EVMN Stock Forecast: Evommune, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Evommune, Inc. is $22. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 11 of 100 as at 21 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Evommune, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Issuance (63): The share count has been shrinking and the company is not leaning on new borrowing.
Momentum (1): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
EVMN stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on EVMN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Of the 20 most recent actions, 0 moved their price target up and 5 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Nov 2026 | Needham | Maintains | Buy | $28 → $25 |
| 12 Oct 2026 | UBS | Initiates | Neutral | $8.00 |
| 9 Sept 2026 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 9 Sept 2026 | Leerink Partners | Maintains | Outperform | $28 → $22 |
| 9 Sept 2026 | RBC Capital | Maintains | Outperform | $29 → $21 |
| 26 Aug 2026 | Needham | Initiates | Buy | $28 |
| 7 Aug 2026 | RBC Capital | Maintains | Outperform | $30 → $29 |
| 3 Aug 2026 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 30 June 2026 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 30 June 2026 | Morgan Stanley | Maintains | Overweight | $55 → $26 |
| 29 June 2026 | William Blair | Downgrade | Market Perform | — |
| 26 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 May 2026 | Morgan Stanley | Maintains | Overweight | — |
| 10 Apr 2026 | RBC Capital | Reiterates | Outperform | — |
| 18 Mar 2026 | Clear Street | Initiates | Buy | — |
| 18 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 10 Feb 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 22 Jan 2026 | Oppenheimer | Initiates | Outperform | — |
| 8 Jan 2026 | Raymond James | Initiates | Strong Buy | — |
| 6 Jan 2026 | HC Wainwright & Co. | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for EVMN.
This page is one stock. Monday covers all of them.
EVMN appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
EVMN vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Evommune, Inc. returned −62.4% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
EVMN analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 22.4×
- Price / book
- 1.0×
- EV / EBITDA
- —
Cheaper than 7% of US stocks
Cheaper than 70% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −69.5%
- Return on assets
- −42.0%
- Dividend yield
- —
Higher than 18% of US stocks
Higher than 10% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Evommune, Inc. has a market value of $291.1M and an enterprise value of $130.7M.
Revenue in the twelve months to 30 June 2026: $10.0M.
Net income over the same four quarters: −$94.7M, a −946.7% net margin.
Diluted earnings per share, trailing twelve months: −$3.37.
Free cash flow in the twelve months to 30 June 2026: −$74.7M.
Evommune, Inc. employs 48 people — $208K of revenue per employee.
Data provided by Twelve Data
EVMN and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at EVMN’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Evommune, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about EVMN
What is the EVMN stock price forecast for 2026-2027?
The median 12-month analyst price target for Evommune, Inc. is $22, with estimates ranging from $8 to $28. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is EVMN stock a buy right now?
Of the 12 analysts covering Evommune, Inc., 9 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Evommune, Inc. 11 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank EVMN?
As at 21 Nov 2026, Evommune, Inc. ranks 11 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Issuance (63 of 100).
Will EVMN stock go up?
No one can know that. What the data says: the median 12-month target from 12 analysts is $22, and Ticker Nerd's factor model ranks Evommune, Inc. 11 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the EVMN stock forecast for 2030?
No analyst covering Evommune, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for EVMN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $28 over the next 12 months.
How has EVMN stock performed over the past year?
Evommune, Inc. returned -62.4% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Evommune, Inc. do?
Evommune, Inc. is a clinical-stage biotechnology company focused on developing therapies for chronic inflammatory diseases. The company is advancing novel treatments designed to address key drivers of inflammation, with current programs centered on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis.
About Evommune, Inc.
Evommune, Inc. is a clinical-stage biotechnology company focused on developing therapies for chronic inflammatory diseases. The company is advancing novel treatments designed to address key drivers of inflammation, with current programs centered on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its pipeline includes product candidates such as EVO756 and EVO301, which are being developed to target immune pathways involved in these conditions. Evommune’s work is positioned within the broader immunology and inflammation markets, where it aims to support more precise treatment options for patients with persistent inflammatory disorders. Based in Palo Alto, California, Evommune emphasizes research-driven drug development across small-molecule and biologic approaches.
CEO Mr. Luis C. Pena · 48 employees · United States · https://www.evommune.com